Research programme: antibacterials - Helmholtz Centre for Infection Research/Evotec SE
Latest Information Update: 28 Mar 2023
At a glance
- Originator Evotec AG; Helmholtz Centre for Infection Research GmbH
- Developer Evotec SE; Helmholtz Centre for Infection Research GmbH
- Class Antibacterials
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for research development in Bacterial-infections in Germany
- 20 Feb 2019 Helmholtz Centre for Infection Research and Evotec AG enter a research collaboration to develop antibacterial therapeutics
- 20 Feb 2019 Early research in Bacterial infections in Germany (unspecified route)